TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Arctic Bioscience AS ( (DE:9TD) ).
Arctic Bioscience is set to release its Q3 2025 operational update on November 10, 2025, at 07:00 CET, followed by a webcast at 10:00 CET to present the update and results from the HeROPA-trial analysis. This announcement highlights the company’s ongoing efforts to engage with stakeholders and provide transparency about its operations and trial progress, potentially impacting its market positioning and investor relations.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech company that focuses on developing and commercializing pharmaceutical and nutraceutical products derived from unique bioactive marine compounds. The company is working on HRO350, an innovative oral drug candidate aimed at treating mild-to-moderate psoriasis, a condition affecting a large patient population in need of effective and safe treatment options. Additionally, Arctic Bioscience markets nutraceuticals globally, both as bulk ingredients and finished goods under the ROMEGA® brand.
Average Trading Volume: 78,795
Current Market Cap: NOK96.16M
See more data about 9TD stock on TipRanks’ Stock Analysis page.